J Zhejiang Univ Sci B . Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China

[tetano]

J Zhejiang Univ Sci B


. 2020 Dec.;21(12):948-954.
doi: 10.1631/jzus.B2000204.
Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China


Yong-Zheng Guo ¹ , Kai-Jin Xu ¹ , Yong-Tao Li ¹ , Jia-Dan Fu ¹ , Min Xu ¹ , Ling Yu ¹ , Ji-Fang Sheng ¹ , Biao Zhu ¹



Affiliations

• PMID: 33843160
• DOI: 10.1631/jzus.B2000204

Abstract

The aim of this study was to evaluate the safety of an antiviral regimen of protease inhibitors combined with Arbidol (umifenovir) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients. The genomic sequence of SARS-CoV-2 is highly homologous to that of SARS-CoV (Zhou et al., 2020). Previously published basic and clinical research on anti-SARS-CoV treatment found that lopinavir/ritonavir (LPV/r) could improve the prognosis of SARS patients (Chan et al., 2003; Chu et al., 2004). Darunavir (DRV) is another protease inhibitor that blocks the binding of SARS-CoV-2 to human angiotensin-converting enzyme 2 (Omotuyi et al., 2020). The broad-spectrum antiviral drug Arbidol (umifenovir) also shows in vitro anti-SARS-CoV activity (Khamitov et al., 2008).

Keywords: SARS-CoV; Lopinavir; Darunavir; Pneumonia; Lipid metabolism.